Table 2 Safety and outcomes.
Median (IQR) | LMOD group n = 6 | Control group n = 5 |
|---|---|---|
Primary outcome and safety | ||
Vasopressor support (epinephrine dose equivalent) at day 1 | 16 (8.7–25) | 10 (3.5–20) |
Vasopressor support (epinephrine dose equivalent) at day 5 | 14.5 (8–20) * | 16 (4.5–45) |
WC at D1 (G/L) | 13 (11–17) | 19 (11–21) |
WC at D5 (G/L) | 15 (9–16) | 14 (5–27) |
Lymphocytes at D1 (G/L) | 0.8 (0.6–1.4) | 1.1 (0.6–2) |
Lymphocytes at D5 (G/L) | 1 (0.5–1.8) | 0.65 (0.5–1.2) |
Thombocytes at D1 (G/) | 221 (168–260) | 266 (232–280) |
Thombocytes at D5 (G/L) | 156 (145–247) | 251 (220–395) |
Secondary outcomes | ||
SOFA at D1 | 13.5 (12.25–15.25) | 11 (10–14) |
SOFA at D5 | 11.5 (10–13.5) | 12 (9–13) |
CRP at D1 (mg/L) | 186 (44–306) | 63 (29–220) |
CRP at D5 (mg/L) | 125 (51–208) | 85 (17–163) |
Ferritin (umol/L) D1 | 2061 (1088–3268) | 1174 (793–3555) |
Ferritin (umol/L) D5 | 1096 (495–3670) * | 823 (710–1650) |
D-Dimere (μg/L) D1 | 7706 (2684–15,694) | 4025 (2088–8460) |
D-Dimere (μg/L) D5 | 3559 (2210–7038) | 2340 (2081–2738) |
Troponin (ng/L) D1 | 61 (27–640) | 38 (14–115) |
Troponin (ng/L) D5 | 43 (20–517) | 47 (17–90) |
AST at D1 (U/L) | 48 (37–107) | 48 (40–80) |
AST at D1 (U/L) | 45 (36–118) | 56 (49–65) |
